Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Baker BROS. Advisors LP

Baker BROS. Advisors LP increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 77.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,670,762 shares of the biotechnology company’s stock after buying an additional 731,588 shares during the quarter. Arrowhead Pharmaceuticals comprises approximately 0.4% of Baker BROS. Advisors LP’s investment portfolio, making the stock its 25th biggest holding. Baker BROS. Advisors LP’s holdings in Arrowhead Pharmaceuticals were worth $57,625,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Cantor Fitzgerald L. P. raised its stake in Arrowhead Pharmaceuticals by 14.7% in the 3rd quarter. Cantor Fitzgerald L. P. now owns 19,500 shares of the biotechnology company’s stock worth $673,000 after acquiring an additional 2,500 shares during the last quarter. Bank of America Corp DE grew its stake in Arrowhead Pharmaceuticals by 21.5% during the 3rd quarter. Bank of America Corp DE now owns 760,687 shares of the biotechnology company’s stock valued at $26,236,000 after purchasing an additional 134,691 shares during the last quarter. Boothbay Fund Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 34.6% in the third quarter. Boothbay Fund Management LLC now owns 83,388 shares of the biotechnology company’s stock worth $2,876,000 after purchasing an additional 21,441 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 2.7% in the third quarter. Ameriprise Financial Inc. now owns 274,163 shares of the biotechnology company’s stock worth $9,456,000 after purchasing an additional 7,136 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 12.8% during the third quarter. Schonfeld Strategic Advisors LLC now owns 543,916 shares of the biotechnology company’s stock worth $18,760,000 after purchasing an additional 61,861 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARWR has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 10th. Piper Sandler restated an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. The Goldman Sachs Group increased their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 7th. Finally, Chardan Capital boosted their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $81.67.

Insider Activity

In related news, CEO Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $68.85, for a total value of $8,950,500.00. Following the completion of the transaction, the chief executive officer owned 3,971,255 shares in the company, valued at $273,420,906.75. The trade was a 3.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James C. Hamilton sold 40,164 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider directly owned 171,958 shares of the company’s stock, valued at $10,852,269.38. The trade was a 18.93% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 495,836 shares of company stock worth $32,759,810. 3.60% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $55.05 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The company has a 50 day moving average price of $64.47 and a 200-day moving average price of $51.36. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $76.76. The firm has a market cap of $7.71 billion, a price-to-earnings ratio of 35.98 and a beta of 1.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business’s quarterly revenue was up 10461.3% on a year-over-year basis. During the same period last year, the company posted ($1.39) earnings per share. Equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.